Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers seek genetic clues to identify addicts and patients who will benefit from treatment

29.07.2002


Toxicology experts have long known that individuals can exhibit a wide range of physiological responses when exposed to identical doses of opiate- or morphine-based drugs. This drug class includes illicit drugs such as heroin, as well as regulated drugs like methadone and oxycontin, which have legitimate uses in addiction treatment and pain management. Unfortunately, an individual’s response to these drugs can be gauged only after the drug has been administered, leaving care givers to make an educated guess as to how much drug to give in order to achieve the intended effect.



Now, a team of researchers suggests that “pharmacogenomic” testing may be a way to help drug-treatment centers select appropriate treatment regimens for their opiate-addicted patients, and it may also provide valuable information in the care of patients who require substantial levels of pharmacological pain management.

Background


The most common treatment for heroin addiction is methadone, used because of its ability to produce psychic and physical dependence, but with significantly milder withdrawal symptoms than heroin. Previously published studies have documented methadone toxicity and noted a higher risk in the initial treatment periods for some patients.

Scientists know that the toxicity of this synthetic narcotic is affected in part by a patient’s metabolism of the drug. Methadone is metabolized by enzymes CYP1A2, CYP2D6 and CYP 3A4. CYP 2D6 is unique in that it is also a key to the metabolism of other opioids, such as codeine and tricyclic antidepressants.

A recent peer-reviewed article—“Pharmacogenomics as Molecular Autopsy for Forensic Pathology/Toxicology: Does Genotyping CYP 296 Serve as an Adjunct for Certifying Methadone Toxicity?”—looks at the possibility of using laboratory-based testing to identify genetic polymorphisms that affect the way an individual metabolizes the opioid class of drugs. The authors are Steven H. Wong, PhD; Michael A. Wagner, PhD; Jeffrey M. Jentzen, MD; Chuck Shur; Jeanette Bjerke; Susan B. Gock; and Chung-Che Jeffrey Chang, MD, PhD, all with the Department of Pathology, Medical College of Wisconsin in Milwaukee. Drs. Wong, Wagner, Jentzen, and Ms. Gock are also affiliated with the Milwaukee County Medical Examiner’s Office.

Results

In their current study, the authors conclude that complex medical and prescription histories often make it difficult to conclude that a CYP 2D6-encoded enzyme deficiency is the sole cause of a methadone mortality, or even contributed to death. They also note that the results generated by their genotyping investigations would not have prompted a change in the medical examiners ruling on cause of death. Nevertheless, the authors say that their study is an important first step in the effort to link genotyping with individuals’ responses to treatment therapies such as methadone, and that establishing this relationship will have a great impact in drug-abuse treatment and pain management.


This study is being presented at the 54th Annual Meeting of the American Association for Clinical Chemistry (AACC) in Orlando, Fla., July 29-August 1, 2002. AACC (http://www.aacc.org/) is the scientific organization for clinical laboratory professionals, physicians, and research scientists. Their primary commitment is the understanding of laboratory testing to identify, monitor and treat human disease. More than 14,000 attendees are expected for the meeting, which is being held at the Orange County Convention Center, Orlando, Fla., July 28-August 1, 2002.

Donna J. Krupa | EurekAlert!
Further information:
http://www.aacc.org

More articles from Health and Medicine:

nachricht Discovery shows promise for treating Huntington's Disease
05.08.2020 | Ecole Polytechnique Fédérale de Lausanne

nachricht Carbon monoxide improves endurance performance
05.08.2020 | Universität Bayreuth

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: ScanCut project completed: laser cutting enables more intricate plug connector designs

Scientists at the Fraunhofer Institute for Laser Technology ILT have come up with a striking new addition to contact stamping technologies in the ERDF research project ScanCut. In collaboration with industry partners from North Rhine-Westphalia, the Aachen-based team of researchers developed a hybrid manufacturing process for the laser cutting of thin-walled metal strips. This new process makes it possible to fabricate even the tiniest details of contact parts in an eco-friendly, high-precision and efficient manner.

Plug connectors are tiny and, at first glance, unremarkable – yet modern vehicles would be unable to function without them. Several thousand plug connectors...

Im Focus: New Strategy Against Osteoporosis

An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.

Osteoporosis is the most common age-related bone disease which affects hundreds of millions of individuals worldwide. It is estimated that one in three women...

Im Focus: AI & single-cell genomics

New software predicts cell fate

Traditional single-cell sequencing methods help to reveal insights about cellular differences and functions - but they do this with static snapshots only...

Im Focus: TU Graz Researchers synthesize nanoparticles tailored for special applications

“Core-shell” clusters pave the way for new efficient nanomaterials that make catalysts, magnetic and laser sensors or measuring devices for detecting electromagnetic radiation more efficient.

Whether in innovative high-tech materials, more powerful computer chips, pharmaceuticals or in the field of renewable energies, nanoparticles – smallest...

Im Focus: Tailored light inspired by nature

An international research team with Prof. Cornelia Denz from the Institute of Applied Physics at the University of Münster develop for the first time light fields using caustics that do not change during propagation. With the new method, the physicists cleverly exploit light structures that can be seen in rainbows or when light is transmitted through drinking glasses.

Modern applications as high resolution microsopy or micro- or nanoscale material processing require customized laser beams that do not change during...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“Conference on Laser Polishing – LaP 2020”: The final touches for surfaces

23.07.2020 | Event News

Conference radar for cybersecurity

21.07.2020 | Event News

Contact Tracing Apps against COVID-19: German National Academy Leopoldina hosts international virtual panel discussion

07.07.2020 | Event News

 
Latest News

Rare Earth Elements in Norwegian Fjords?

06.08.2020 | Earth Sciences

Anode material for safe batteries with a long cycle life

06.08.2020 | Power and Electrical Engineering

Turning carbon dioxide into liquid fuel

06.08.2020 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>